BackMera Pharmaceuticals Overview

Mera Pharmaceuticals EBIT

Mera Pharmaceuticals's EBIT is $-200K, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$103.55K
↑ 73.94% YoY

As of Oct 31, 2011

Annual EBIT (TTM)

-$196.06K
↑ 64.49% YoY

Trailing 12 months ending Oct 31, 2011

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Mera Pharmaceuticals (MRPI) FAQ

Mera Pharmaceuticals posts a EBIT of $-200K as of October 2011. That compares with $-550K in the prior-year period — up 64.5% year over year. That is below the Healthcare sector average of $1.9T. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Mera Pharmaceuticals's EBIT was $-550K. The latest reading is $-200K — a 64.5% year-over-year increase (period ending October 2011). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a EBIT near $1.9T is typical. Mera Pharmaceuticals's $-200K is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Mera Pharmaceuticals's financial statement story. At $-200K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for MRPI's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $1.9T), and (3) consistency with growth and profitability. This page covers the first two; Mera Pharmaceuticals's other metric pages and overview cover the third.